American Academy of Family Physicians

Printer-friendly version

Share this on AAFP Connection

Share this page

FDA Links Hydroxycut Weight Loss Supplements to Liver Damage

Manufacturer Recalls More Than a Dozen Products

By News Staff

The FDA is warning consumers to stop using many Hydroxycut weight loss products because they can cause liver and other serious health problems, possibly leading to death.
FDA Advisory
According to Linda Katz, M.D., M.P.H., interim chief medical officer with the FDA's Center for Food Safety and Applied Nutrition, the agency has received 23 reports of adverse events in users of these Hydroxycut products, including asymptomatic liver enzyme changes, jaundice, liver damage requiring liver transplant and liver failure resulting in one death.

Katz said several additional cases of liver failure resolved when patients stopped taking Hydroxycut.

In conjunction with the FDA warning, Iovate Health Sciences Inc., of Oakville, Ontario, and Iovate Health Sciences USA Inc. of Blasdell, N.Y., makers of Hydroxycut products, announced a recall of more than a dozen of the weight loss products from the market.

"Although the liver damage appears to be relatively rare, FDA contends the consumer should not be exposed to unnecessary risk," Katz said. "FDA continues to investigate the potential relationship between the use of Hydroxycut dietary supplements and liver injury and other potentially serious side effects."

Katz said the FDA has not determined which Hydroxycut ingredient dosages may be associated with the risk of developing liver disease. She said there were overlapping ingredients in the recalled products, but no single ingredient was common to all the products.

The FDA is advising consumers to discontinue use of Hydroxycut weight loss products and to consult a physician if they are experiencing any symptoms of liver injury, including jaundice, brown urine, nausea, vomiting, light colored stools, unusual tiredness, weakness, stomach or abdominal pain, unexplained itching, and loss of appetite. Other health problems related to the use of Hydroxycut products reported to the FDA include seizures, cardiovascular disorders and rhabdomyolysis.

Physicians or patients should report any adverse events associated with the use of dietary supplements to the FDA's MedWatch Program online or by calling (800) 332-1088.

Hydroxycut's Cleanse and Hoodia products are not affected by the recall.

Share this on AAFP Connection

Health of the Public

Study: PPI Does Not Routinely Improve Asthma Control

Recalled Oral Contraceptives Pose Pregnancy Risk

CDC to Fund 2D Vaccine Barcoding Pilot

2012 Immunization Schedules Reflect Multiple Changes

Study: Cognitive Decline Detected in Middle-aged Adults

CDC Toolkit Can Help Clinicians Fight Norovirus Infection

Patient-Centered Care Linked to Lower Mortality

Study: Inappropriate Cancer Screenings Continue

Novartis Manufacturing Plant Closes After Drug Mix-ups

FDA Announces Classwide REMS for TIRF Medications

New Infants' Acetaminophen Products Hit Store Shelves

Avoid Environmental Factors Linked to Breast Cancer

Risk for Thrombosis Prompts REMS for Rivaroxaban

Common Drugs Implicated in Most Emergency Hospitalizations

CDC Launches Campaign for Child Medication Safety

HHS Blocks Expanded OTC Access to Plan B

Push Is On to Vaccinate Pregnant, Postpartum Women

FDA Committee Votes to Broaden PCV13 Indication

AAFP Foundation Program Aims to Fight Chronic Disease

NIAAA Alcohol Screening Guide Targets Teens

Walgreens, AAFP Launch Flu Vaccine Pilot in Five States

Helping Patients Quit Smoking Starts With a Question

Trilipix Efficacy in Question, Says FDA

USPSTF Addresses Skin Cancer, Obesity, Cervical Cancer Screening

AAFP Endorses ACP Guideline on ED

ACIP Recommends Expanded HPV, Hepatitis B Vaccination

Bacterial Contamination Spurs Nasal Spray Recall

CDC Renews Call for PCV13 Vaccination

USPSTF Recommends Against PSA Screening

AAFP Supports HHS' Million Hearts Initiative

FDA Phases Out Primatene Mist Inhalers

AHRQ Guides Explain Benefits, Risks of GERD Treatments

Tar Wars Winner Gives Back

Office Champions Project Nets Smoking Cessation Gains

Multiple Lots of Oral Contraceptives Recalled

New Vaccine Review Finds Few Adverse Events

HPV Vaccination Rates Still Lag, Says CDC

Renal Injury Prompts Reclast Label Changes

High-dose Citalopram Linked to Abnormal Heart Rhythms

AHRQ Sleep Apnea Guides Review Diagnosis, Management

Board Chair Spotlights Breadth of Family Medicine Training

USPSTF Softens Stance on Bladder Cancer Screening

HHS Expands Coverage for Women's Preventive Services

Teledermatology Project Aids Underserved Patients

New Chantix Warnings Cite Cardiovascular Risk

Pertussis Outbreaks Lead to CDC Alert on PCR Testing